Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one systematic review(s)/meta-analysis(es). ^[1]
• Highly Emetogenic Chemotherapy (HEC): For complete control of vomiting during days 1-5, fosnetupitant + palonosetron was the most effective combination with 810 of 1000 participants achieving control (RR (relative risk) 1.15, 95% CI (confidence interval) 0.97-1.37; moderate certainty), followed by aprepitant + palonosetron with 753 of 1000 participants (RR 1.07, 95% CI 0.98-1.18; low certainty).
• Moderately Emetogenic Chemotherapy (MEC): Rolapitant + granisetron achieved higher vomiting control in MEC patients with 660 of 1000 participants (RR 1.19, 95% CI 1.06-1.33; high certainty), while aprepitant + palonosetron also showed efficacy with 716 of 1000 participants (RR 1.29, 95% CI 1.00-1.66; low certainty).
• Comparative Efficacy: In HEC, netupitant + palonosetron and fosaprepitant + granisetron demonstrated similar efficacy to aprepitant + granisetron, with 704 and 697 of 1000 participants achieving vomiting control, respectively (RR 1.00, 95% CI 0.93-1.08 for netupitant and RR 0.99, 95% CI 0.93-1.06 for fosaprepitant; high certainty).
• Highly Emetogenic Chemotherapy (HEC): Fosaprepitant + ondansetron, casopitant + ondansetron, and netupitant + palonosetron were associated with fewer serious adverse events (SAEs), with occurrences of 8 to 9 per 1000 participants (RRs between 0.23 to 0.27, low certainty) compared to aprepitant + granisetron. Rolapitant + granisetron had a slightly higher rate of SAEs at 20 per 1000 participants (RR 0.57, 95% CI 0.19 to 1.70; low certainty).
• Moderately Emetogenic Chemotherapy (MEC): Rolapitant + granisetron was associated with a higher rate of SAEs compared to granisetron alone, occurring in 176 of 1000 participants (RR 1.15, 95% CI 0.88 to 1.50; low certainty).
• There is no population types or subgroups information available in the reviewed studies.